Hypothesis

Beta-hydroxybutyrate (BHB) restores NAD+ levels not only by inhibiting class I HDACs but also by directly stimulating the NAD+ salvage enzyme NAMPT through a GPR109A‑PKA signaling axis. If this dual mechanism operates in aging humans, then BHB supplementation will raise intracellular NAD+, reactivate sirtuins, and produce coordinated improvements across multiple hallmarks of aging (genomic stability, epigenetics, mitochondria, proteostasis, nutrient sensing) measurable in a large cohort.

Mechanistic Rationale

1. HDAC inhibition → NAMPT transcription – As shown in C. elegans and rotifers, BHB’s class I HDAC inhibition lifts repression of the NAMPT promoter, increasing NAD+ biosynthesis [2, 4].

2. GPR109A‑PKA activation → NAMPT stabilization – BHB is an agonist of the hydroxycarboxylic acid receptor 2 (GPR109A/HCAR2). Activation raises cAMP, activates PKA, which phosphorylates NAMPT at Ser^XX, protecting it from proteasomal degradation. This post‑translational boost complements transcriptional upregulation, creating a synergistic rise in NAD+.

3. NAD+ surge → sirtuin reactivation → hallmark coordination – Elevated NAD+ fuels SIRT1‑7 activity, deacetylating targets that govern DNA repair (PARP1, Ku70), histone modifiers (HDACs, HATs), mitochondrial biogenesis (PGC‑1α), autophagy (FOXO3), and metabolic sensors (AMPK, LKB1). Thus a single molecular shift can simultaneously attenuate several hallmarks.

Testable Predictions

• In a double‑blind, placebo‑controlled trial (n≥1,000 adults aged 60‑80), 12 weeks of oral BHB (e.g., ketone ester) will increase fasting blood NAD+ by ≥15 % relative to placebo (primary endpoint).
• The NAD+ increase will be significantly larger in participants with baseline low NAMPT mRNA (measured in PBMCs) or high GPR109A expression (stratification analysis).
• Concomitant improvements will be observed in at least three of the following hallmark biomarkers:
  • Genomic stability: reduced γ‑H2AX foci in circulating lymphocytes.
  • Epigenetic age: ΔGrimAge ≤‑1.0 year.
  • Mitochondrial function: ↑ maximal OXPHOS capacity in isolated PBMCs.
  • Proteostasis: ↓ plasma carb‑ylated proteins and ↑ lysosomal cathepsin activity.
  • Nutrient sensing: ↑ p‑AMPK/TSC2 ratio.
• If BHB fails to raise NAD+ or does not produce coordinated biomarker shifts despite adequate plasma ketone levels, the hypothesis that BHB acts via a NAD+‑centric upstream controller is falsified.

Falsifiability Criteria

• Null outcome: No significant NAD+ change (p>0.05) or NAD+ rise without corresponding improvements in ≥2 hallmark markers.
• Alternative outcome: NAD+ increase occurs but hallmark biomarkers remain unchanged, suggesting NAD+ elevation alone is insufficient to drive multi‑hallmark coordination.
• Mechanistic refutation: Blocking GPR109A (with antagonist) or PKA (with H‑89) in ex‑vivo PBMC cultures abolishes BHB‑induced NAMPT stabilization and NAD+ rise, confirming the receptor‑mediated arm; lack of effect would falsify the proposed signaling route.

Implementation Sketch

• Recruit from existing aging cohorts; collect baseline PBMCs for NAMPT/GPR109A qPCR, plasma NAD+ metabolomics, and hallmark panels.
• Randomize to BHB ester (equiv. to 30 g β‑hydroxybutyrate/day) vs. isocaloric placebo.
• Follow‑up at 0, 6, and 12 weeks; repeat assays.
• Use mixed‑effects models to test interaction between treatment, baseline NAMPT/GPR109A, and biomarker trajectories.

Significance

Demonstrating that a single exogenous ketone can simultaneously engage transcriptional and post‑translational control of NAD+ biosynthesis would bolster the idea that aging hallmarks are orchestrated by a tunable metabolic node. Conversely, a negative result would push the search for upstream controllers beyond NAD+‑centric models, encouraging exploration of other systemic regulators (e.g., circulating GDF15, lysosomal signaling) as potential master coordinators.